NASDAQ · MOLN
Healthcare · Biotechnology
$4.20
Up+$0.18 (+4.48%)
Updated Sep 16, 2026, 11:23 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 16 trading sessions · Daily adjusted prices
MOLN closed at $4.20 after 16 trading sessions, down 2.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.99 | $4.20 | $3.90 | $4.20 | 3.67K |
| Sep 14, 2026 | $4.15 | $4.15 | $4.00 | $4.02 | 1.63K |
| Sep 10, 2026 | $4.18 | $4.20 | $4.18 | $4.18 | 1.07K |
| Sep 4, 2026 | $4.35 | $4.35 | $4.35 | $4.35 | 2.17K |
| Sep 3, 2026 | $4.35 | $4.35 | $4.35 | $4.35 | 282.24 |
| Sep 2, 2026 | $4.07 | $4.07 | $4.07 | $4.07 | 282.24 |
| Sep 1, 2026 | $4.3799 | $4.3799 | $4.285 | $4.285 | 968.24 |
| Aug 28, 2026 | $4.67 | $4.67 | $4.50 | $4.50 | 1.55K |
| Aug 27, 2026 | $4.60 | $4.6524 | $4.56 | $4.6524 | 4.72K |
| Aug 26, 2026 | $4.49 | $4.49 | $4.42 | $4.45 | 2.39K |
| Aug 25, 2026 | $4.35 | $4.38 | $4.1301 | $4.38 | 2.11K |
| Aug 24, 2026 | $4.30 | $4.40 | $4.30 | $4.40 | 1.91K |
| Aug 21, 2026 | $4.38 | $4.3999 | $4.38 | $4.3999 | 504.56 |
| Aug 20, 2026 | $4.24 | $4.25 | $4.23 | $4.23 | 3.66K |
| Aug 19, 2026 | $4.30 | $4.3301 | $4.30 | $4.3301 | 443.24 |
| Aug 18, 2026 | $4.245 | $4.29 | $4.245 | $4.29 | 534.24 |
The latest Smart Investors Daily articles mentioning MOLN.
MOLN research
Company profile and research snapshot.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 6, 2026 | TD COWEN | Buy | — |
| Feb 2, 2026 | CLEAR STREET LLC | Buy | — |
| Feb 2, 2026 | TD COWEN | Buy | — |
| Feb 1, 2026 | CLEAR STREET LLC | Buy | — |
| Dec 15, 2025 | CLEAR STREET LLC | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 25, 2026
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.45) by 95.56 percent. This is a 31.34 percent decrease over losses of $(0.67) per share
Benzinga · Jul 16, 2026
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoingData update expected in 2027, with trial completion in 2028Trial-in-progress poster to be
Benzinga · Jul 15, 2026
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacyPresentation outlines Radio-DARPins’ ability to match target and disease biology for
Benzinga · Jul 6, 2026
Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MOLN.
